• β-Elemene Suppresses Adipogenesis via AMPK Activation in 3T3

  2026-08-05

  This study elucidates how β-elemene inhibits adipogenesis and reverses insulin resistance in 3T3-L1 adipocytes by activating the AMPK pathway. The findings provide a mechanistic basis for β-elemene’s potential as a molecular tool in obesity and metabolic research.

• CX-5461 Induces Mitotic Catastrophe and Sensitizes Cervical

  2026-08-04

  This study demonstrates that the RNA polymerase I inhibitor CX-5461 potently suppresses cervical cancer cell growth by inducing DNA damage, activating the ATM/ATR pathway, and triggering mitotic catastrophe. It also shows that CX-5461 enhances cisplatin sensitivity, supporting its therapeutic potential for chemoresistant cervical cancer.

• (-)-Arctigenin as a Precision MEK1 Inhibitor in Cancer Workf

  2026-08-04

  (-)-Arctigenin empowers translational researchers with unparalleled mechanistic precision as both a MEK1 inhibitor and anti-inflammatory agent, uniquely supporting studies on tumor microenvironment crosstalk and NF-κB signaling. This guide delivers actionable workflow enhancements, troubleshooting strategies, and protocol-level insights to maximize the impact of APExBIO’s Arctigenin in bench-to-bedside oncology and immunology research.

• PrLGlu/avBNSTGABA Circuit Rapidly Modulates Depression in Mi

  2026-08-03

  This study identifies the glutamatergic prelimbic to GABAergic anterior ventral BNST (PrLGlu/avBNSTGABA) circuit as a rapid modulator of depression-like behaviors in male mice. Using chemogenetic and optogenetic approaches, the work shows targeted activation of this pathway produces swift antidepressant effects, with significant implications for understanding and treating depression.

• Protein A/G Magnetic Beads: Technical Guidance for Antibody

  2026-08-03

  Protein A/G Magnetic Beads (SKU K1305) address common challenges in antibody purification and protein-protein interaction workflows by providing high specificity and reduced background binding. Designed for applications such as immunoprecipitation, co-IP, and Ch-IP, these beads are not intended for diagnostic or clinical use and should be avoided in workflows requiring non-IgG antibody capture.

• 3-Aminobenzamide (PARP-IN-1): Transforming PARP Inhibition W

  2026-08-02

  3-Aminobenzamide (PARP-IN-1) unlocks precision in poly (ADP-ribose) polymerase inhibition, enabling robust, reproducible results for oxidative stress, endothelial function, and diabetic nephropathy models. Its proven IC50 and workflow adaptability set a new benchmark for applied research and troubleshooting. Discover how APExBIO’s offering empowers advanced experimental designs and cross-domain innovation.

• Antiseptics for Burns: Efficacy, Limitations, and Research I

  2026-08-01

  This Cochrane review systematically evaluated the comparative effects of antiseptics—including topical antibiotics—on burn wound healing, infection rates, and adverse events. The findings highlight the nuanced efficacy of silver-based dressings versus antibiotic therapies, underscoring the need for evidence-based selection of antimicrobial strategies in burn care and infection research models.

• IPA-3: Unraveling Pak1 Autoinhibition for Advanced Neuroinfl

  2026-07-31

  Explore how IPA-3, a selective Pak1 inhibitor, enables precise manipulation of kinase signaling in neuroinflammation and cancer biology research. This article offers a mechanistic deep dive, recent reference insights, and advanced protocol guidance distinct from standard workflows.

• Annexin V-PE Apoptosis Detection Kit: Rapid, Live-Cell Assay

  2026-07-31

  The Annexin V-PE Apoptosis Detection Kit from APExBIO empowers researchers with fast, fixation-free apoptosis detection directly in live cells. Its one-step protocol and high sensitivity make it a top choice for dissecting cell death pathways and evaluating therapeutic interventions in translational studies.

• Berberine Targets RXRα/PPARγ/NEDD4 to Limit SASP in Atherosc

  2026-07-30

  This study reveals that berberine suppresses senescence-associated secretory phenotype (SASP)–driven inflammation in atherosclerosis by modulating the RXRα/PPARγ/NEDD4 pathway in macrophage-derived foam cells. Mechanistic insights highlight the regulation of ubiquitination and transcriptional activity, providing novel targets for addressing chronic vascular inflammation and cellular senescence.

• UK-5099 in Immune Metabolism: Beyond Protocols to Mechanisti

  2026-07-30

  Explore how UK-5099 (PF-1005023) advances mitochondrial metabolism research and immune assay innovation. This in-depth analysis reveals mechanistic insights and practical strategies for leveraging UK-5099 in cutting-edge immunometabolic studies.

• Deferasirox Fe3+ Chelate: Optimizing Iron Overload Research

  2026-07-29

  Deferasirox Fe3+ chelate (Exjade) enables precise modeling of iron overload and chelation in chronic anemia and beta-thalassemia studies. This guide delivers actionable protocol enhancements, troubleshooting strategies, and advanced use-cases to maximize research impact using APExBIO’s high-purity reagent.

• 3-Aminobenzamide (PARP-IN-1): Reliable PARP Inhibition for C

  2026-07-29

  This article delivers scenario-driven insights for biomedical researchers and lab technicians leveraging 3-Aminobenzamide (PARP-IN-1), SKU A4161, in viability, cytotoxicity, and mechanistic studies. Integrating quantitative data and cited evidence, we address common assay challenges and protocol optimizations, highlighting why APExBIO’s 3-Aminobenzamide offers reproducibility and confidence across experimental workflows.

• Coronavirus Macrodomains: PARP-Mediated Antiviral Defense Un

  2026-07-28

  The reference study identifies coronavirus macrodomains as key viral factors that counteract poly (ADP-ribose) polymerase (PARP)-mediated inhibition of viral replication and enhance interferon (IFN) expression. This work reveals a crucial interplay between host PARP enzymes and viral macrodomains, illuminating new avenues for antiviral research and targeted inhibition of viral immune evasion.

• Berberine Modulates RXRα/PPARγ/NEDD4 to Suppress Atheroscler

  2026-07-28

  This study demonstrates that berberine inhibits senescence-associated secretory phenotype (SASP) inflammation in atherosclerosis via the RXRα/PPARγ/NEDD4 pathway. Mechanistic dissection reveals how berberine-induced PPARγ activation and enhanced NEDD4-mediated ubiquitination converge to degrade pro-inflammatory complexes in foam cells, highlighting therapeutic avenues for vascular aging.

15932 records 1/1063 page Next 12345 下5页 Last page